12-Month Data from Surmodics SurVeil & #194; & #174; Drug-Coated Balloon Early Feasibility ...

Study met primary endpoint and all 12-month secondary safety endpoints including 100 percent freedom from CD-TLR or TVR Results demonstrated continued clinically significant improvement in ABI, walking distance, walking speed and stair-climbing scores at 12 months EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced that data from the PREVEIL early feasibility study (EFS) of...This story is related to the following:Medical Balloons
Source: Industrial Newsroom - Health, Medical and Dental Supplies - Category: Medical Devices Source Type: news
More News: Medical Devices | Study